Form 4 for QNRX Quoin Pharmaceuticals Ltd.

Accepted 2024-12-27 00:00:00 ET · period of report 2024-12-23 · accession 0001104659-24-132188 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2024-12-27	2024-12-23	QNRX	Myers Michael	CEO, Dir	P - Purchase	$0.45	+555.6K	602.8K	+1,176%	+$250.0K
DM	2024-12-27	2024-12-23	QNRX	Myers Michael	CEO, Dir	P - Purchase	—	+1.11M	555.6K	New	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Ordinary Shares	2024-12-23	P	A	555,556	$0.45	602,808	D	—	—	(F1) Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.
2	Derivative	Series F Warrants (right to buy)	2024-12-23	P	A	555,556	—	555,556	D	$0.45 · 2024-12-23 to 2026-12-23	555,556 ADS	(F2) Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants." (F3) The Warrants were exercisable immediately, subject to a beneficial ownership cap.
3	Derivative	Series G Warrants (right to buy)	2024-12-23	P	A	555,556	—	555,556	D	$0.45 · 2024-12-23 to 2029-12-24	555,556 ADS	(F2) Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants." (F3) The Warrants were exercisable immediately, subject to a beneficial ownership cap.